KFM19

CAS No. 133058-72-7

KFM19( —— )

Catalog No. M33392 CAS No. 133058-72-7

KFM19 is a potent and selective adenosine receptor (A1-receptor) antagonist (IC50 : 50 nM) for the study of neurological disorders.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 90 In Stock
10MG 131 In Stock
25MG 247 In Stock
50MG 356 In Stock
100MG 507 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    KFM19
  • Note
    Research use only, not for human use.
  • Brief Description
    KFM19 is a potent and selective adenosine receptor (A1-receptor) antagonist (IC50 : 50 nM) for the study of neurological disorders.
  • Description
    KFM19 is a potent, selective Adenosine receptor (A1-receptor) antagonist, with an IC50 of 50 nM.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    GPCR/G Protein
  • Target
    Adenosine Receptor
  • Recptor
    Adenosine Receptor
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    133058-72-7
  • Formula Weight
    318.37
  • Molecular Formula
    C16H22N4O3
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 100 mg/mL (314.10 mM; Ultrasonic )
  • SMILES
    CCCn1c2[nH]c(nc2c(=O)n(CCC)c1=O)C1CCC(=O)C1
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. W.D. Bechtel, et al. KFM 19 antagonizes the adenosine-induced inhibition of electrically evoked acetylcholine release. Eur Neuropsychopharmacol. Sep. 1993, 3(3), Page 433
molnova catalog
related products
  • Tozadenant

    A potent, selective adenosine 2A receptor (A2A/NR2B) antagonist with Ki of 11.5 nM.

  • SCH 412348

    SCH 412348 is a potent and highly selective A2A receptor competitive antagonist with Ki of 0.6 nM.

  • Ciforadenant

    A potent, orally active, adenosine A2A receptor antagonist that is being investigated in solid tumors as a single agent and in combination with the anti-PD-L1 antibody atezolizumab.